Recent Events & Conferences


APIFINY® is the only cancer specific, non-PSA blood test technology that may aid clinicians in the assessment of risk for the presence of prostate cancer.

APIFINY blood tests measure unique biological markers known to be associated with an immune system response to prostate cancer. Test results may provide clinicians with additional insight into a patient’s risk, which may aid in a clinical decision for determining next steps.

Supporting Literature

- “Since this novel autoantibody technology measures different biologic parameters than PSA, it may provide additional useful information for physicians involved in the management of patients at risk for PCA (Prostate Cancer).”
- “New biomarkers, such as autoantibody signatures, may improve the early detection of prostate cancer…Autoantibodies against peptides derived from prostate-cancer tissue could be used as the basis for a screening test for prostate cancer.”

Breakthrough Science for Assessing Cancer Risk


In the case of most cancers, the earlier the detection, the better chance for recovery. Scientific discovery has come a long way in the detection of lung, breast, and prostate cancers. However, there remains a potential for missed diagnosis. Armune BioScience was founded on the mission to improve the detection of cancer and enhance the outcome of therapies to treat cancer. Our technology is based on peer-reviewed and validated scientific research that measures specific biological markers known to be associated with an immune system response to cancer.

Learn More

What is Prostate Cancer and How is it Detected?

Prostate Cancer Detection

Prostate cancer is the most common non-skin cancer in America, affecting 1-in-7 men. In this section, we provide an overview of prostate cancer and the methods currently available to test and assess risk for, diagnose, and treat the disease.

Learn More